Рет қаралды 5,755
Dr. Marisa Weiss, Chief Medical Officer of Breastcancer.org, discusses the results of the KATHERINE study at the 2018 San Antonio Breast Cancer Symposium. The study found that women with early-stage, HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy had better outcomes with Kadcyla compared to Herceptin. Read more about this study here: www.breastcanc....